Brean Murray Carret & Co. Starts IntelliPharmaCeutics International (IPCI) at Buy

Brean Murray Carret & Co. initiates coverage on IntelliPharmaCeutics International (NASDAQ: IPCI) with a Buy. PT $7.00.

Brean analyst said, "We see several near-term catalysts for Intellipharmaceutics, notably its second Phase 1 Rexista dataset, a potential Rexista partnership, and initiation of Phase 3 Rexista trials. Positive Phase 1 data for Rexista could lead to a partnership that generates a significant upfront payment. Also, Phase 3 initiation, expected in 1Q13, would clarify Rexista’s potential market timing."

For an analyst ratings summary and ratings history on IntelliPharmaCeutics International click here. For more ratings news on IntelliPharmaCeutics International click here.

Shares of IntelliPharmaCeutics International closed at $2.86 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cantor Fitzgerald Starts Incyte (INCY) at Neutral, 'JAK-ing Up Its Pipeline In Advance of a Major Patent Cliff'
• Citi Starts Privia Health Group Inc (PRVA) at Buy
• BofA Securities Reinstates Mahanagar Gas Limited (MAHGL:IN) at Buy